Pediatric Medicine
Page 1 • 3 itemsAccess global pediatric medicine market intelligence. Discover drug development, regulatory insights, and investment opportunities for children's health.
Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11
Sanofi and Regeneron's Dupixent receives FDA approval as the first biologic treatment for pediatric chronic spontaneous urticaria in children 2-11 years old.
Ipsen's Ojemda (Tovorafenib) Becomes First Targeted Therapy for Pediatric Brain Tumors in EU
Ipsen's Ojemda receives EU approval as first targeted therapy for pediatric low-grade glioma, addressing critical unmet need in rare brain tumors.
Sanofi's Tzield Receives FDA Approval for Children as Young as 1 Year to Delay Type 1 Diabetes Progression
FDA approves Sanofi's Tzield for children aged 1+ with stage 2 type 1 diabetes, marking the first disease-modifying therapy for this pediatric population.